Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

  1. Université Paris Cité, AP-HP, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l’Adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France
  2. Corresponding author: Charles Ouazana-Vedrines, MD, Service de Psychiatrie de l’Adulte, Hôpital Hôtel-Dieu, 1 Place du Parvis Notre-Dame, 75004 Paris, France ([email protected]).
  3. Department of Pathologies and Patients, Caisse Nationale d’Assurance Maladie, Paris, France
  4. Department of Pathologies and Patients, Caisse Nationale d’Assurance Maladie, Paris, France
  5. Université Paris Cité, AP-HP, Hôpital Corentin-Celton, DMU Psychiatrie et Addictologie, Service de Psychiatrie et d’Addictologie de l’Adulte et du Sujet Âgé, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S126, Issy-les-Moulineaux, France
  6. Population-based Epidemiological Cohorts Unit, UMS 011 Inserm-UVSQ, Villejuif, France
  7. Department of Psychiatry, New York State Psychiatric Institute/Columbia University, New York, New York
  8. Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse, Bethesda, Maryland
  9. Université Paris Cité, AP-HP, Hôpital Corentin-Celton, DMU Psychiatrie et Addictologie, Service de Psychiatrie et d’Addictologie de l’Adulte et du Sujet Âgé, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S126, Issy-les-Moulineaux, France
  10. Department of Pathologies and Patients, Caisse Nationale d’Assurance Maladie, Paris, France
  11. Department of Pathologies and Patients, Caisse Nationale d’Assurance Maladie, Paris, France
  12. Université Paris Cité, AP-HP, Hôpital Hôtel-Dieu, DMU Psychiatrie et Addictologie, Service de Psychiatrie de l’Adulte, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, Paris, France
  1. Cuijpers P, Vogelzangs N, Twisk J, et al. Comprehensive meta-analysis of excess mortality in depression in the general community versus patients with specific illnesses. Am J Psychiatry. 2014;171(4):453–462. PubMed CrossRef
  2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. PubMed CrossRef
  3. Hoertel N, Franco S, Wall MM, et al. Mental disorders and risk of suicide attempt: a national prospective study. Mol Psychiatry. 2015;20(6):718–726. PubMed CrossRef
  4. Turecki G, Brent DA. Suicide and suicidal behaviour. Lancet. 2016;387(10024):1227–1239. PubMed CrossRef
  5. Depression overview - NICE Pathways. NICE website. https://pathways.nice.org.uk/pathways/depression. 2020.
  6. Traitement par antidépresseurs. ANSM: Agence Nationale de Sécurité du Médicament et des Produits de Santé. 2019. https://archiveansm.integra.fr/Dossiers/Traitements-par-antidepresseurs/Traitement-par-antidepresseurs/(offset)/0
  7. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. 2010. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf.
  8. Gabriel FC, de Melo DO, Fráguas R, et al. Pharmacological treatment of depression: a systematic review comparing clinical practice guideline recommendations. PLoS One. 2020;15(4):e0231700. PubMed CrossRef
  9. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299–2312. PubMed CrossRef
  10. Trivedi MH, Rush AJ, Wisniewski SR, et al; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. PubMed CrossRef
  11. Stein MB, Sareen J. Clinical Practice: generalized anxiety disorder. Solomon CG, ed. N Engl J Med. 2015;373(21):2059–2068. >
  12. Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23. PubMed CrossRef
  13. MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23. PubMed CrossRef
  14. Souery D, Serretti A, Calati R, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31(4):512–516. PubMed CrossRef
  15. Malhi GS, Bell E, Singh AB, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disord. 2020;22(8):788–804. PubMed CrossRef
  16. Boyce P, Hopwood M, Morris G, et al. Switching antidepressants in the treatment of major depression: when, how and what to switch to? J Affect Disord. 2020;261:160–163. PubMed CrossRef
  17. Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019;12(12):CD010557. PubMed CrossRef
  18. Blanco C, Olfson M, Goodwin RD, et al. Generalizability of clinical trial results for major depression to community samples: results from the National Epidemiologic Survey on alcohol and related conditions. J Clin Psychiatry. 2008;69(8):1276–1280. PubMed CrossRef
  19. Franco S, Hoertel N, McMahon K, et al. Generalizability of pharmacologic and psychotherapy clinical trial results for posttraumatic stress disorder to community samples. J Clin Psychiatry. 2016;77(8):e975–e981. PubMed CrossRef
  20. Weisberg HI, Hayden VC, Pontes VP. Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clin Trials. 2009;6(2):109–118. PubMed CrossRef
  21. Humphreys K, Harris AHS, Weingardt KR. Subject eligibility criteria can substantially influence the results of alcohol-treatment outcome research. J Stud Alcohol Drugs. 2008;69(5):757–764. PubMed CrossRef
  22. Hoertel N, Falissard B, Humphreys K, et al. Do clinical trials of treatment of alcohol dependence adequately enroll participants with co-occurring independent mood and anxiety disorders? an analysis of data from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry. 2014;75(3):231–237. PubMed CrossRef
  23. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. PubMed CrossRef
  24. Olekhnovitch R, Hoertel N, Limosin F, et al. Using filled prescription sequences to rank antidepressants according to their acceptability in the general population: the Constances cohort. J Psychiatr Res. 2020;123:72–80. PubMed CrossRef
  25. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(8):954–962. PubMed CrossRef
  26. Tuppin P, de Roquefeuil L, Weill A, et al. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique. 2010;58(4):286–290. PubMed CrossRef
  27. Constantinou P, Tuppin P, Fagot-Campagna A, et al. Two morbidity indices developed in a nationwide population permitted performant outcome-specific severity adjustment. J Clin Epidemiol. 2018;103:60–70. PubMed CrossRef
  28. Verhaak PFM, de Beurs D, Spreeuwenberg P. What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? a longitudinal cohort analysis. BMJ Open. 2019;9(2):e024051. PubMed CrossRef
  29. Hansen DG, Vach W, Rosholm J-U, et al. Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics. Fam Pract. 2004;21(6):623–629. PubMed CrossRef
  30. Blanco C, Rafful C, Olfson M. The use of clinical trials in comparative effectiveness research on mental health. J Clin Epidemiol. 2013;66(suppl):S29–S36. PubMed CrossRef
  31. Blanco C, Campbell AN, Wall MM, et al. Toward national estimates of effectiveness of treatment for substance use. J Clin Psychiatry. 2017;78(1):e64–e70. PubMed CrossRef
  32. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162(7):1370–1372. PubMed CrossRef
  33. Sox HC, Lewis RJ. Pragmatic trials: practical answers to “real world” questions. JAMA. 2016;316(11):1205–1206. PubMed CrossRef
  34. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–1886. PubMed CrossRef
Purchase PDF for $40

Members enjoy free PDF downloads on all articles. Join today

Save Save

Share Share

Cite Cite

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe now